New shot could help control bleeding in hemophilia a

NCT ID NCT05987449

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests a new drug, NXT007, in people with severe or moderate hemophilia A. The drug is given as a shot under the skin, first every two weeks, then every four weeks. The goal is to see if it is safe and helps control bleeding. About 60 adults, teens, and children will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NXT007 (also called Zemocimig or RO7589655)
What this could lead to: If successful, this could lead to a new treatment option that helps control bleeding in people with hemophilia A, reducing the need for frequent infusions.
What could go wrong: This is an early phase I/II trial with only 60 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or not work as expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA A

Contacts and locations

Locations

Auckland Cancer Trial Centre
RECRUITING

Auckland, 1023, New Zealand
British Columbia Children's Hospital
RECRUITING

Vancouver, British Columbia, V6H 3N1, Canada
Georgetown Uni Medical Center
WITHDRAWN

Washington D.C., District of Columbia, 20007, United States
Hamilton Health Sciences Corporation
RECRUITING

Hamilton, Ontario, L8N 3Z5, Canada
Hospital Regional Universitario Carlos Haya
ACTIVE_NOT_RECRUITING

Málaga, 29010, Spain
Hospital Sant Joan de Deu
RECRUITING

Esplugues de Llobregat, Barcelona, 08950, Spain
Hospital Universitario la Paz
ACTIVE_NOT_RECRUITING

Madrid, 28046, Spain
IRCCS Ca' Granda Ospedale Maggiore Policlinico
RECRUITING

Milan, Lombardy, 20122, Italy
Indiana Hemophilia & Thrombosis center
RECRUITING

Indianapolis, Indiana, 46260, United States
Instytut Hematologii i Transfuzjologii
RECRUITING

Warsaw, 02-776, Poland
Istituto Clinico Humanitas
RECRUITING

Rozzano (MI), Lombardy, 20089, Italy
UC Davis Cancer Center
RECRUITING

Sacramento, California, 95817, United States
University of Iowa Hospitals and Clnics Dept of Pediatrics
RECRUITING

Iowa City, Iowa, 52242, United States
Uniwersyteckie Centrum Kliniczne
RECRUITING

Gda?sk, 80-214, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.